Supernus Pharmaceuticals and Indivior have signed an all-stock merger agreement to form a CNS-focused company, combining their marketed neurological and substance-use disorder portfolios. The merged entity will be based in Rockville, Maryland, and keep the Supernus name under the transaction structure described in reporting. The combination is positioned to consolidate neuroscience commercialization and clinical development resources. The deal is framed around cost and portfolio synergy, with the companies citing improved focus on central nervous system therapeutics. For CNS competitors, the merger reduces the number of independently positioned commercial neuroscience players and could intensify competition for attention, prescribing, and payer coverage across opioid use disorder and Parkinson’s-related segments.